EDGAR·FLOW

MAXCYTE, INC. — Form 8-K

Filed November 10, 2026 · analyzed by the 8-K Agent
8-K — Neutral significance 72/100
What the filing says
MaxCyte (MXCT, $231M market cap) is acquiring Ohio Intermediate LLC and related entities (collectively 'Acquired Companies,' primarily BioP) from Ohio TopCo LP and Arcline Capital Partners for: (1) Estimated Closing Cash Payment (subject to working capital adjustment), (2) Stock Consideration (unspecified share count, <20% of MaxCyte), and (3) $20M in Deferred Payments ($10M each in 2028 and 2029). Transaction dated November 9, 2026, with Closing expected ~120 days thereafter pending HSR clearance. Deal includes $10M-$20M earnout-like deferred components and assumes Acquired Companies' indebtedness and transaction expenses.
Why this rating

Material acquisition funded by mix of cash/stock/deferred payments; deal scale relative to $231M market cap material but not transformational; execution risk on HSR approval and working capital finalization; non-compete/standstill terms protect sellers' stock position.

Price action (we called it neutral)
before filing · preread
$1.35 ▼ 3.20%
at our read · unknown
$1.40
+10 min · unknown
$1.39 ▼ 0.36%
+30 min · unknown
$1.38 ▼ 1.08%
+1 hr · unknown
$1.26 ▼ 9.68%
+4 hrs · unknown
$1.13 ▼ 19.00%

The stock had already moved +3.31% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ MXCT · stock on Yahoo Finance ↗

See more from November 10, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.